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Abstract 
A direct and convenient spectrophotometric assay has been developed for methionine aminopeptidases 
(MetAPs). The method employs the hydrolysis of a substrate that is a methionyl analogue of p-nitroaniline (l-
Met-p-NA), which releases the chromogenic product p-nitroaniline. This chromogenic product can be monitored 
continuously using a UV–Vis spectrophotometer set at 405 nm. The assay was tested with the type I MetAP from 
Escherichia coli (EcMetAP-I) and the type II MetAP from Pyrococcus furiosus (PfMetAP-II). Using l-Met-p-NA, the 
kinetic constants kcat and Km were determined for EcMetAP-I and PfMetAP-II and were compared with those 
obtained with a “standard” high-performance liquid chromatography (HPLC) discontinuous assay. The assay has 
also been used to determine the temperature dependence of the kinetic constant kcat for PfMetAP-II as well as 
to screen two novel pseudopeptide inhibitors of MetAPs. The results demonstrate that l-Met-p-NA provides a 
fast, convenient, and effective substrate for both type I and type II MetAPs and that this substrate can be used 
to quickly screen inhibitors of MetAPs. 
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Introduction 
Angiogenesis is a crucial step in the pathogenesis of numerous human diseases, including diabetic retinopathy, 
rheumatoid arthritis, and cancer [1], [2], [3], [4]. It has been shown that malignant tumors cannot grow and 
metastasize without the formation of new blood vessels that provide oxygen, nutrients, and various growth 
factors. In addition, tumors use newly formed blood vessels to disseminate invasive tumor cells. Thus, the 
inhibition of angiogenesis is a promising strategy for the treatment of cancer. TNP-470, a synthetic derivative of 
a fungal metabolite fumagillin, was one of the first antiangiogenesis agents to enter clinical trials [5]. The activity 
of this sesquiterpene epoxide-containing molecule was evaluated for the treatment of a variety of cancers such 
as Kaposi’s sarcoma, cervical cancer, brain cancer, and renal cell carcinoma [6]. Based on fumagillin affinity 
chromatography and mass spectrometry, methionine aminopeptidases (MetAPs)1 were identified as the 
molecular targets of fumagillin and TNP-470 [7], [8]. Furthermore, in vivo studies showed that one of the 
observed effects of inhibiting MetAPs by antiangiogenesis agents is the failure to expose glycine residues at the 
N termini of certain signaling proteins involved in cell cycle regulation, which prevents myristolyation [9]. 
Therefore, MetAPs are an extremely promising target for the design of a novel class of antiangiogenesis drugs, 
some of which currently are under clinical investigation [5], [10], [11], [12], [13], [14], [15], [16], [17], [18]. 
 
MetAPs are capable of the hydrolytic removal of an N-terminal methionine residue from nascent polypeptide 
chains [19], [20], [21], [22]. Because the biosynthesis of all eukaryotic proteins present in the cytosol starts with 
the initiator methionine, MetAPs play a central role in protein synthesis [23]. The structure of mature N termini 
plays important roles in N-directed degradation pathways and in targeting cellular membranes [24], [25]. 
Therefore, MetAPs are one of the key cellular enzymes involved in protein maturation. MetAPs are organized 
into two classes (types I and II) based on the absence or presence of an extra 62-amino acid sequence (of 
unknown function) inserted near the catalytic domain of type II enzymes. The type I MetAPs from Escherichia 
coli (EcMetAP-I), Staphylococcus aureus (SaMetAP-I), Thermotoga maritime (TmMetAP-I), and Homo sapiens 
(HsMetAP-I), and the type II MetAPs from Homo sapiens (HsMetAP-II) and Pyrococcus furiosus (PfMetAP-II), 
have been characterized crystallographically [26], [27], [28], [29], [30], [31], [32]. All six display a novel “pita 
bread” fold with an internal pseudo-twofold symmetry that structurally relates the first and second halves of the 
polypeptide chain to each other. Each half contains an antiparallel β-pleated sheet flanked by two helical 
segments and a C-terminal loop. Both domains contribute conserved residues to the metallo-active site. In all 
five structures, a bis(μ-carboxylato)(μ-aquo/hydroxo)dicobalt(II) core is observed with an additional carboxylate 
residue at each metal site and a single histidine bound to Co1. 
 
A major issue that has plagued research efforts on MetAPs is the lack of a fast and simple spectrophotometric 
assay. To date, the most widely used assay involves determining the amount of product (l-Met) formed by high-
performance liquid chromatography (HPLC) [33], [34], [35]. Even though this assay is very accurate, it is very 
time-consuming and expensive to run. To develop a simple, inexpensive, and fast continuous assay for MetAPs, 
here we report the monitoring of amide bond cleavage by both type I and type II MetAPs using a methionyl 
analogue of p-nitroaniline (l-Met-p-NA). Proof of concept that this assay is functional is shown by comparison of 
kinetic data obtained with l-Met-p-NA with the peptide substrate MGMM using a discontinuous HPLC assay. We 
also use l-Met-p-NA to investigate the potency of two new MetAP inhibitors. 
Materials and methods 
Protein expression, purification, and metal activation 
EcMetAP-I and PfMetAP-II were purified as described previously [12], [33]. Purified EcMetAP-I and PfMetAP-II 
exhibited single bands on sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS–PAGE) at Mr 29,630 
and Mr 32,850, respectively. Protein concentrations for EcMetAP-I and PfMetAP-II were estimated from the 
absorbance at 280 nm using extinction coefficients of 16,445 and 21,650 M−1 cm−1, respectively [12], [33], [35]. 
Apo-EcMetAP-I was washed free of methionine using Chelex-100-treated methionine-free buffer (25 mM Hepes 
[pH 7.5] and 150 mM KCl) and was concentrated by microfiltration using a Centicon-10 (Amicon, Beverly, MA, 
USA) prior to all kinetic assays. Individual aliquots of apo-EcMetAP-I were routinely stored at −80 °C or in liquid 
nitrogen until needed. Apo-EcMetAP-I and apo-PfMetAP-II samples used in catalytic measurements were made 
rigorously anaerobic prior to incubation with 3 eq of Co(II) (CoCl2, ⩾99.999%, Strem Chemicals, Newburyport, 
MA, USA) for approximately 30 min at 20–25 °C. Co(II)-containing samples were handled throughout in an 
anaerobic glove box (Ar/5% H2, ⩽1 ppm O2, Coy Laboratories, Ann Arbor, MI, USA) until frozen. Electronic 
absorption measurements were performed on a Shimadzu UV-3101PC spectrophotometer. 
 
Discontinuous enzymatic assay of MetAPs 
All enzymatic assays were performed under strict anaerobic conditions in an inert atmosphere glove box (Coy 
Laboratories) with a dry bath incubator to maintain the temperature. Catalytic activities were determined with 
an error of ±5% using the substrate MGMM in 25 mM Chelex-100-treated methionine-free Hepes buffer (pH 7.5) 
containing 150 mM KCl. The amount of product (l-Met) formation was determined by HPLC (Shimadzu LC-10A 
class-VP5). A typical assay involved the addition of 8 μl of metal-loaded WT EcMetAP-I enzyme to a 32-μl 
substrate–buffer mixture at 30 °C for 1 min. The reaction was quenched by the addition of 40 μl of a 1% 
trifluoroacetic acid (TFA) solution. Elution of the product was monitored at 215 nm following separation on a C8 
HPLC column (Phenomenex Luna, 5 μm, 4.6 × 25 cm), as described previously [33], [34], [35]. 
 
Synthesis of l-MetStaCys and l-MetStaVal 
l-MetStaCys and l-MetStaVal were synthesized by solid-phase synthesis on Rink Amide AM resin using an N-Boc-
protected statine derivative of l-Met, (3S,4S)-4-tert-butoxycarbonylamino-3-hydroxy-6-methylsulfanyl-hexanoic 
acid, which was prepared according to Jouin and co-workers [36]. This synton (1.4 eq) was attached to resin-
bound Val or Cys(Trt) (1 eq) using N,N′-diisopropylcarbodiimide (3 eq) and N-hydroxybenzotriazole (5 eq) as 
coupling agents in a mixture of N-methylpyrrolidinone and dichloromethane overnight. Pseudopeptides were 
cleaved off the resin with a mixture of 97% TFA, 1% ethanedithiol, 1% trisopropylsilane, and 1% water. The 
inhibitors were purified using HPLC and characterized by mass spectrometry. 
Results and discussion 
Several discontinuous assays have been reported, with the most used ones being (i) HPLC detection of the 
reaction product l-Met, (ii) amino acid oxidase together with horseradish peroxidase and monitoring of the 
absorbance at 440 nm [24], [37], [38], and (iii) reaction of l-Met with a chromogenic or fluorogenic tag and 
analysis of the derivatives by HPLC or by capillary electrophoresis [39], [40]. Although these assays are indeed 
functional, several problems exist for all of them (e.g., long incubation times, time-consuming, labor-intensive, 
expensive, significant background noise). Recently, two complementary, continuous MetAP assays were 
reported [41]. In the first, a thioester substrate was used; on exposure of the free thiol group by the action of 
MetAP, the amount of free thiol was quantified by 5,5′-dithio-bis(2-nitrobenzoic) acid (DTNB) [41]. Although a 
creative approach to assay MetAPs, DTNB is known to inactivate EcMetAP-I (and likely all type I MetAPs) by 
modifying active site cysteine residues [42]. Alternatively, a coupled spectrophotometric assay in which the 
dipeptide substrate Met-Pro-p-NA was employed was reported [41]. In this assay, the N-terminal methionine 
residue was removed by MetAP, followed by cleavage of l-Pro by a prolyl aminopeptidase, releasing p-
nitroaniline [41]. Although this assay is relatively simple to use, one major problem involves cross-reactivity of 
potential MetAP inhibitors when attempting to obtain Ki values. To overcome problems with the currently 
available assay methods for MetAPs, we have examined amide bond cleavage by both type I and type II MetAPs 
using a methionyl analogue of p-nitroaniline (l-Met-p-NA). 
 
Recently, it was shown that HsMetAP-II could use substrates smaller than dipeptides, such as l-methionine-7-
amido-4-methylcoumarin (l-Met-AMC) and l-Met-p-NA, whereas EcMetAP-I was shown to hydrolyze l-Met from 
l-Met-AMC [43]. However, it was reported previously that yeast MetAP-I was unable to cleave l-Met-p-NA [44]. 
Even so, we hypothesized that both type I and type II MetAPs could hydrolyze l-Met-p-NA, contrary to previous 
reports [24]. Therefore, the hydrolytic activity of Co(II)-reconstituted EcMetAP-I and PfMetAP-II was examined 
with l-Met-p-NA as the substrate. A typical reaction of 1, 4, or 12 μM PfMetAP-II or EcMetAP-I with l-Met-p-NA 
was carried out at 30 °C in a quartz cuvette containing 25 mM Hepes buffer at pH 7.5 with 150 mM KCl and 
monitoring the absorbance at 405 nm (ε = 10,800 M−1 cm−1) for 10 min. The rate of background hydrolysis of l-
Met-p-NA was measured by monitoring the formation of p-nitroaniline continuously at 405 nm and was 
subtracted. Interestingly, the absorbance at 405 nm in the presence of PfMetAP-II or EcMetAP-I increased 
linearly with time (Fig. 1), and the amount of product released was linearly dependent on the concentration of 
the enzyme (Fig. 2). As a control, l-Ala-p-nitroaniline and l-Leu-p-nitroaniline were examined, and (as expected) 
neither PfMetAP-II nor EcMetAP-I could use these substrates. These data clearly show that l-Met-p-NA can 
function as a substrate for both type I and type II MetAPs. 
 
 
Fig. 1. Time course for the hydrolysis of l-Met-p-NA (1 mM) by EcMetAP-I (4 μM) and PfMetAP-II (1 μM) in 
25 mM Hepes buffer (pH 7.5) and 150 mM KCl. 
 Fig. 2. Effect of EcMetAP-I (solid triangles) and PfMetAP-II (solid circles) concentration on the hydrolysis of l-
Met-p-NA (1 mM) in 25 mM Hepes buffer (pH 7.5) and 150 mM KCl. 
 
Both PfMetAP-II and EcMetAP-I exhibited saturation kinetics when l-Met-p-NA was used as a substrate (Fig. 3). 
Activity assays using l-Met-p-NA were performed in triplicate and revealed that Co(II)-loaded PfMetAP-II is more 
active than Co(II)-loaded EcMetAP-I (Table 1). Km and kcat values were obtained by nonlinear fitting of the data to 
the Michaelis–Menten equation. For PfMetAP-II, the kcat value observed for l-Met-p-NA at 30 °C was 0.057 s−1 
(Km = 0.59 mM), providing a catalytic efficiency of 97.0 M−1 s−1, whereas EcMetAP-I exhibited a kcat value of 
0.006 s−1 (Km = 0.44 mM), providing a catalytic efficiency of 13.7 M−1 s−1. For comparison purposes, the kinetic 
parameters for Co(II)-loaded EcMetAP-I and Co(II)-loaded PfMetAP-II were determined using MGMM as the 
substrate (Table 1) [35]. Activity assays were performed in triplicate for 8–15 concentrations of MGMM (0–
12 mM), and the product (l-Met) was quantified by a discontinuous HPLC assay [35]. Km and kcat values were 
obtained by nonlinear fitting of the data to the Michaelis–Menten equation. For PfMetAP-II, the kcat value for 
MGMM at 30 °C was 188 s−1 (Km = 5.1 mM), providing a catalytic efficiency of 37,000 M−1 s−1, whereas EcMetAP-I 
exhibited a kcat value of 18.3 s−1 (Km = 3.0 mM), providing a catalytic efficiency of 6100 M−1 s−1. Therefore, both 
EcMetAP-I and PfMetAP-II are much poorer catalysts for the cleavage of l-Met from l-Met-p-NA by 
approximately 440 and 380 times, respectively. Even though the catalytic efficiencies were small, this assay was 
found to be very sensitive and reproducible because l-Met-p-NA binds more tightly to both type I and type II 
MetAPs and the highly chromogenic product that can be monitored continuously at 405 nm. Therefore, the 
simplicity of a direct spectrophotometric assay suggests that l-Met-p-NA is the substrate of choice for analyzing 
MetAP activity. 
 
 Fig. 3. Michaelis–Menten plot for the hydrolysis of l-Met-p-NA by EcMetAP-I (solid circles) and PfMetAP-II (solid 
triangles) in 25 mM Hepes buffer (pH 7.5) and 150 mM KCl. 
 
Table 1. Kinetic constants for Co(II)-loaded EcMetAP-I and PfMetAP-II using MGMM and l-Met-p-NA in 25 mM 
Hepes buffer at 30 °C (pH 7.5) with 150 mM KCl 
  
Kinetic constants l-Met-p-NA MGMM 
EcMetAP-I Km (mM) 0.44 ± 0.03 3.0 ± 0.1  
kcat (s−1) 0.006 18.3  
kcat/Km (M−1 s−1) 13.7 6100  
SA (U/mg) 1.3 × 10−2 36.0     
PfMetAP-II Km (mM) 0.59 ± 0.07 5.1 ± 0.3  
kcat (s−1) 0.057 188  
kcat/Km (M−1 s−1) 97.0 37,000  
SA (U/mg) 1.1 × 10−1 340 
 
It was reported previously [35] that the optimal activity for PfMetAP-II toward MGMM occurred at 85 °C in 
25 mM Hepes (pH 7.5) and 150 mM KCl buffer. Therefore, the hydrolysis of l-Met-p-NA was examined in 
triplicate between 25 and 90 °C at a substrate concentration of 5 mM. The calculated specific activity values 
were plotted as a function of temperature between 25 and 90 °C. The specific activity values for l-Met-p-NA 
hydrolysis catalyzed by Co(II)-loaded PfMetAP-II were found to increase with increasing temperature. In a simple 
rapid equilibrium, Vmax/[E] = kp, the first-order rate constant. Because the enzyme concentration was not altered 
over the course of the experiment, an Arrhenius plot could be constructed by plotting ln(kcat) versus 1/T (Fig. 4). 
The linearity of the Arrhenius plot indicates that the rate-limiting step does not change as a function of 
temperature [45]. From the slope of the line, the activation energy, Ea, for temperatures between 296 and 358 K 
was calculated to be 54 kJ/mol for Co(II)-loaded PfMetAP-II but was 13.3 kJ/mol using MGMM as the substrate 
[35]. These data compare well with the Ea values reported for the aminopeptidase from Aeromonas proteolytica 
(36.5 kJ/mol), which has a similar activation energy to pronase and both thermolysin and carboxypeptidase A 
[46], [47], [48]. The fact that the activation energy is approximately fourfold higher for the hydrolysis of l-Met-p-
NA by Co(II)-loaded PfMetAP-II is constant with the observed decrease in kcat when l-Met-p-NA is used as a 
substrate. 
 
 Fig. 4. Arrhenius plot of ln(kcat) versus 1/T for Co(II)-loaded PfMetAP-II using l-Met-p-NA as the substrate in 
25 mM Hepes buffer (pH 7.5) and 150 mM KCl. 
 
Because the slope of an Arrhenius plot is equal to −Ea1/R, where R = 8.3145 JK−1 mol−1, thermodynamic 
parameters for the hydrolysis of l-Met-p-NA by Co(II)-loaded PfMetAP-II were calculated by the following 
relations: ΔG≠ = −RTln(kcath/kBT), ΔH≠ = Ea − RT, ΔS≠ = (ΔH≠ − ΔG≠) /T, where R, h, and kB are the gas, Boltzmann, 
and Planck constants, respectively (Table 2). The enthalpy of activation calculated over the temperature range 
25–90 °C is 47.5 kJ/mol for Co(II)-loaded PfMetAP-II, whereas the entropy of activation was found to be 
−79.9 J/mol/K at 25 °C. The positive enthalpy, which is approximately four times larger than the enthalpy 
observed using MGMM as the substrate, is indicative of a conformation change on substrate binding likely due 
to the energy of bond formation and breaking during nucleophilic attack on the scissile carbonyl carbon of the 
substrate [35]. On the other hand, the large negative entropy value, which is similar in magnitude to the 
enthalpy observed using MGMM as the substrate (−119.7 J/mol/K), suggests that some molecular motions are 
lost on ES‡ complex formation, possibly due to hydrogen bond formation between catalytically important amino 
acids and the substrate [35]. All of these factors contribute to the large positive free energy of activation 
(71.3 kJ/mol), which is nearly double the value observed using MGMM as the substrate [35]. 
 
Table 2. Thermodynamic parameters for hydrolysis of l-Met-p-NA by Co(II)-loaded PfMetAP-II in 25 mM Hepes 
buffer (pH 7.5) and 150 mM KCl 
  
Ea (kJ/mol) ΔH≠ (kJ/mol) ΔG≠ (kJ/mol) ΔS≠ (J/mol/K) 
l-Met-p-NA 54.0 47.5 71.3 −79.9 
 
Finally, we have designed and synthesized several pseudopeptides that have nonhydrolyzable moiety that 
mimics the transition state of the substrate in the active site of MetAPs that represent a new class of MetAP 
inhibitors. These molecules are based on a statine derivative of l-Met with a Cys (l-MetStaCys, 1) or a Val (l-
MetStaVal, 2) attached to the C terminus of the statine synthon (Fig. 5). Both 1 and 2 were tested for their ability 
to inhibit Co(II)-loaded EcMetAP-I and PfMetAP-II (Fig. 5) using l-Met-p-NA as the substrate. The reaction rates 
of Co(II)-loaded EcMetAP-I and PfMetAP-II in the presence of 0–1 mM of 1 or 2 were monitored continuously at 
405 nm, and the initial rates were calculated. The IC50 values for 1 and 2 were obtained from plots of the ratio of 
the initial rates with and without the inhibitor against inhibitor concentrations (Fig. 6). The IC50 values for 1 
inhibiting Co(II)-loaded EcMetAP-I and PfMetAP-II were found to be 2.5 ± 0.1 and 1.7 ± 0.2 μM, respectively, 
whereas 2 exhibited IC50 values of 4.3 ± 0.4 and 2.0 ± 0.1 μM for Co(II)-loaded EcMetAP-I and PfMetAP-II, 
respectively. The IC50 values observed for 1 and 2 binding to PfMetAP-II using l-Met-p-NA as the substrate 
compare well with IC50 values (1.5 ± 0.1 and 2.0 ± 0.1 μM, respectively) obtained for the Mn(II)-loaded PfMetAP-
II using the discontinuous HPLC assay that uses MGMM as the substrate. These data indicate that using l-Met-p-
NA as a substrate for type I and type II MetAPs provides a fast, convenient, and direct spectrophotometric assay 
with which to screen potential inhibitors of MetAPs. Moreover, these data indicate that the l-MetStaCys and l-
MetStaVal are good inhibitors of both type I and type II MetAPs, suggesting that the l-MetSta scaffolding 
provides an excellent base for the synthesis of new MetAP inhibitors. 
 
 
Fig. 5. Chemical structures of the l-MetStaX (X = Cys, 1, and Val, 2) pseudopeptide MetAP inhibitors. 
 
 
Fig. 6. Dose-dependent curves for the inhibition of EcMetAP-I (solid lines) and PfMetAP-II (dashed lines) by 1 
(circles) and 2 (squares) at 30 °C in 25 mM Hepes buffer (pH 7.5) and 150 mM KCl. 
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1 Abbreviations used: MetAP, methionine aminopeptidase; EcMetAP-I, type I MetAP from Escherichia coli; 
SaMetAP-I, type I MetAP from Staphylococcus aureus; TmMetAP-I, type I MetAP from Thermotoga maritime; 
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